Organogenesis Holdings Lowers FY2026 Sales Guidance from $350.000M-$420.000M to $270.000M-$310.000M vs $401.200M Est

Benzinga Newsdesk www.benzinga.com Negative 96.0%

Neg 96% Neu 0% Pos 0%

Organogenesis Holdings (NASDAQ:ORGO) lowers FY2026 sales outlook from $350.000 million-$420.000 million to $270.000 million-$310.000 million vs $401.200 million estimate.